Get the Stockscreener App
4.37
8.17%
0.33
After Hours:
4.41
0.04
+0.92%
Ironwood Pharmaceuticals Inc stock is traded at $4.37, with a volume of 2.72M.
It is up +8.17% in the last 24 hours and up +29.67% over the past month.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
See More
Previous Close:
$4.04
Open:
$4.2
24h Volume:
2.72M
Relative Volume:
0.92
Market Cap:
$712.56M
Revenue:
$296.15M
Net Income/Loss:
$24.02M
P/E Ratio:
36.24
EPS:
0.1206
Net Cash Flow:
$127.01M
1W Performance:
+24.50%
1M Performance:
+29.67%
6M Performance:
+171.43%
1Y Performance:
+505.10%
1-Day Range:
$4.13
$4.475
1-Week Range:
$3.41
$4.475
52-Week Range:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.37 | 658.76M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals (IRWD) price target increased by 10.31% to 5.46 - MSN
Ironwood (IRWD) is one of the most attractive small-cap drug manufacturers, here is why - MSN
New Highs: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentM&A Rumor & Consistent Profit Alerts - baoquankhu1.vn
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Breakout Move: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2026 Chart Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Support Test: Does Ironwood Pharmaceuticals Inc have consistent dividend growth2026 EndofMonth & High Win Rate Trade Tips - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5.8%Time to Sell? - MarketBeat
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why - Insider Monkey
Range Financial Group LLC Acquires Shares of 426,095 Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 5.4%Still a Buy? - MarketBeat
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? - TradingView
IRWD (Ironwood Pharmaceuticals) Net Income (Discontinued Op - GuruFocus
IRWD (Ironwood Pharmaceuticals) Inventories, Raw Materials & Components : $0.0 Mil (As of Dec. 2025) - GuruFocus
Aug Update: Can Ironwood Pharmaceuticals Inc outperform in the next rallyMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment - Stock Titan
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Ironwood Pharmaceuticals (IRWD) Tops Small-Cap Growth List - GuruFocus
IRWD Stock Price, Quote & Chart | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Sarissa Capital Management LP Reduces Stake in Ironwood Pharmace - GuruFocus
Ironwood Pharmaceuticals | 10-K: FY2025 Annual Report - Moomoo
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9%Time to Buy? - marketbeat.com
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Will Linzess continue to aid IRWD's top line in 2026 after a soft Q4? - MSN
Market Pulse: Is Ironwood Pharmaceuticals Inc forming a breakout patternCEO Change & Scalable Portfolio Growth Methods - baoquankhu1.vn
Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD) - The Globe and Mail
Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8% - Stock Titan
Aug Rallies: Is Ironwood Pharmaceuticals Inc affected by consumer sentiment2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Pullback Watch: How much upside does Ironwood Pharmaceuticals Inc have2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 6,730,800 Shares of Stock - MarketBeat
Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals director Denner sells $20.5m in shares - Investing.com
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale - Stock Titan
Breakouts Watch: Is Ironwood Pharmaceuticals Incs growth already priced in2026 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 15.8% in February - MarketBeat
Trade Report: Can Ironwood Pharmaceuticals Inc outperform in the next rallyWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award - Stock Titan
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant - Stock Titan
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award - Stock Titan
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award - Stock Titan
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - The Globe and Mail
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ironwood Pharmaceuticals Inc Stock (IRWD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):